APA (7th ed.) Citation

MS, B., A, F., RH, S., A, V., M, L., L, C., . . . M, E. (2026). CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: A reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. The Lancet. Oncology, 27(5), 592. https://doi.org/10.1016/S1470-2045(26)00053-7

Chicago Style (17th ed.) Citation

MS, Beshr, et al. "CDK4/6 Inhibitors Plus Endocrine Therapy Versus Endocrine Monotherapy in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Reconstructed Individual Patient Data Meta-analysis of Phase 3 Randomised Controlled Trials." The Lancet. Oncology 27, no. 5 (2026): 592. https://doi.org/10.1016/S1470-2045(26)00053-7.

MLA (9th ed.) Citation

MS, Beshr, et al. "CDK4/6 Inhibitors Plus Endocrine Therapy Versus Endocrine Monotherapy in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Reconstructed Individual Patient Data Meta-analysis of Phase 3 Randomised Controlled Trials." The Lancet. Oncology, vol. 27, no. 5, 2026, p. 592, https://doi.org/10.1016/S1470-2045(26)00053-7.